This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
by Ahan Chakraborty
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
PFENegative Net Change AMPHNegative Net Change CRMDNegative Net Change MIRMNegative Net Change
biotechnology biotechs medical pharmaceuticals
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
by Ekta Bagri
BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.
BDTXNegative Net Change CGEMNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector
HALOPositive Net Change ANIPNegative Net Change KNSANegative Net Change TWSTNegative Net Change AKRONegative Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Sell Stocks for September 23rd
by Zacks Equity Research
ATS, ASRT and DBVT have been added to the Zacks Rank #5 (Strong Sell) List on September 23, 2025.
DBVTNegative Net Change ASRTNegative Net Change ATSNegative Net Change
biotechnology
Company News for Sep 23, 2025
by Zacks Equity Research
Companies In The News Are: ORCL, TAP, AAPL, MTSR, PFE.
AAPLNegative Net Change PFENegative Net Change ORCLNegative Net Change TAPPositive Net Change MTSRNegative Net Change
biotechnology consumer-staples pharmaceuticals tech-stocks
Implied Volatility Surging for Eton Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to ETON stock based on the movements in the options market lately.
ETONNegative Net Change
biotechnology biotechs medical
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
by Zacks Equity Research
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
REGNPositive Net Change SNYPositive Net Change CRMDNegative Net Change KNSANegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
by Zacks Equity Research
The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.
SNYPositive Net Change CRMDNegative Net Change KNSANegative Net Change PHARPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk Hold Its Edge as the GLP-1 Battle With LLY Heats Up?
by Zacks Equity Research
NVO gains ground in the GLP-1 battle as Ozempic outshines Trulicity in heart risk reduction and Rybelsus wins EU approval for added benefits.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Bristol Myers Squibb's Restructuring Program Boost Earnings Growth?
by Ekta Bagri
Bristol Myers ramps up a $2.5B restructuring plan to cut costs, streamline operations, and offset pressure from generic competition.
BMYNegative Net Change NVONegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Jefferies (JEF) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
JEFNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Shattuck Labs, Inc. (STTK) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
STTKNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
by Zacks Equity Research
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
NVSNegative Net Change QGENPositive Net Change INCYNegative Net Change
biotechnology biotechs medical pharmaceuticals
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
by Zacks Equity Research
Roche is set to acquire 89bio for $3.5B, adding late-stage MASH drug pegozafermin to its cardiovascular, renal, and metabolic pipeline.
GSKPositive Net Change NVSNegative Net Change RHHBYPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
by Ekta Bagri
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
ILMNNegative Net Change BEAMNegative Net Change WVENegative Net Change CRSPNegative Net Change TWSTNegative Net Change WGSNegative Net Change
biotechnology biotechs gene-editing genetics genomics medical pharmaceuticals
LLY's Orforglipron Tops NVO's Oral Pill in Diabetes Study: What's Next?
by Zacks Equity Research
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
by Ahan Chakraborty
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
PFENegative Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
After Golden Cross, Strawberry Fields REIT, Inc. (STRW)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
STRWPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
by Zacks Equity Research
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
INCY Announces New Late-Stage Data on Skin Disease Drug
by Zacks Equity Research
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
NVSNegative Net Change INCYNegative Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
by Ahan Chakraborty
Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
by Ahan Chakraborty
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
PFENegative Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Pyxis Oncology, Inc. (PYXS) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PYXSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Howard Hughes Holdings (HHH) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
HHHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
by Zacks Equity Research
Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals